CORMEDIX
CorMedix Inc. is a specialty pharmaceutical company that develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Specifically, our goal is to treat human disease by reducing commonly associated renal, cardiovascular, metabolic and infectious complications. Our therapeutic candidates may be small molecules, biologics, chemical entities, devices and/or diagnostics (molecular/lab tests) that enable targeted therapy in these areas. CorMedix has re... ceived CE Mark approval for Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients. Our goal is to provide risk mitigation solutions for central venous catheters (CVCs) in a variety of important indications.
CORMEDIX
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2006-01-01
Address:
Bridgewater, New Jersey, United States
Country:
United States
Website Url:
http://www.cormedix.com
Total Employee:
11+
Status:
Active
Contact:
908-517-9500
Total Funding:
11.47 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API WordPress Font Awesome Wordpress Plugins Sitelinks Search Box Microsoft Exchange Online
Similar Organizations
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Board_member
2015-01-01
Current Employees Featured
Randy Milby CEO @ CorMedix
CEO
Richard M. Cohen CFO @ CorMedix
CFO
Founder
Stock Details
Official Site Inspections
http://www.cormedix.com Semrush global rank: 3.49 M Semrush visits lastest month: 4.29 K
- Host name: 151.101.2.159
- IP address: 151.101.2.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "CorMedix"
Management Team - CorMedix | Prevention of cardiac, renal and ...
Prior to joining CorMedix, Erin was Vice President of Market Access at Intarcia Therapeutics responsible for pricing, coverage, access, Real world evidence (RWE) and channel strategy …See details»
CorMedix - Crunchbase Company Profile & Funding
CorMedix Inc. is a specialty pharmaceutical company that develops and seeks to commercialize products for the treatment of cardiac, renal and infectious …See details»
Prevention of cardiac, renal and infectious diseases - CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. …See details»
CorMedix Inc. Company Profile | Berkeley Heights, NJ
Company Description: CorMedix is a commercial-stage biopharmaceutical company which seeks to in-license, develop, and commercialize therapeutic products for the prevention and …See details»
CorMedix, Inc. - AnnualReports.com
CorMedix, Inc., a development-stage biopharmaceutical company, develops, manufactures, and markets products that lock a patient's central venous catheter between hemodialysis sessions …See details»
CorMedix, Inc. - Drug pipelines, Patents, Clinical trials
Joe Todisco, CorMedix CEO, commented, “CorMedix applauds CMS for making a patient-centered policy change that will align provider incentives with patient care and broaden access to innovation. I am appreciative of the industry …See details»
The Facts About CRBSIs | CorMedix Inc.
Scroll down for helpful resources and to connect with a CorMedix representative. CRBSI Fact Sheet. Get the facts about CRBSIs and how they affect HD-CVC patients . VIEW AND DOWNLOAD PDF. CRBSI Risks & Financial Impact. …See details»
Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A …
4 hours ago Cormedix Inc (CRMD) reports its first profitable quarter with strong revenue growth and strategic partnerships, despite challenges in price erosion and customer expansion.See details»
CorMedix, Inc.
Joe Todisco, CorMedix CEO, commented “We are excited to announce our collaboration with such an established and successful government sales organization fully dedicated to the VA …See details»
CorMedix Inc. Announces Leadership Updates and Operational
May 12, 2022 Joe Todisco, Chief Executive Officer of CorMedix, officially joined the organization on Tuesday May 10 th. ...See details»
CORMEDIX INC. REPORTS FOURTH QUARTER AND …
22 hours ago Berkeley Heights, NJ – March 25, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and …See details»
CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial ...
23 hours ago CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening …See details»
CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce …
Nov 15, 2023 Our commercial team along with our broader organization is preparing for commercial launch, and we look forward to working with healthcare providers and facilities to …See details»
CorMedix Inc. Reports Fourth Quarter and Full Year 2022 Financial ...
Mar 30, 2023 CorMedix was informed by its primary contract manufacturing organization (“CMO”) that all corrective actions stemming from the FDA’s June 2022 inspection have been …See details»
CorMedix targets $50M-$60M revenue for H1 2025 with …
1 day ago Earnings Call Insights: CorMedix Inc. (CRMD) Q4 2024. Management View. CEO Joe Todisco highlighted the commercial success of DefenCath, noting net revenue of $31.2 million …See details»
CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial ...
1 day ago CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Provided by GlobeNewswire Mar 25, 2025 11:30am ‒ Q4 2024 Net …See details»
CorMedix Inc. Announces Partnership With The Leapfrog Group
Dec 4, 2023 About CorMedix. CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life …See details»
CorMedix Inc. Reports Q4 2024 Net Revenue of $31.2 Million and …
23 hours ago Potential Positives. CorMedix reported its first profitable commercial quarter with net income of $13.5 million for Q4 2024, a significant turnaround from a net loss of $14.8 …See details»
CorMedix (CRMD) Q4 2024 Earnings Call Transcript
22 hours ago CorMedix achieved profitability in the fourth quarter as our net income was 13.5 million, or $0.22 per share, compared with the net loss of 14.8 million or $0.26 per share in the …See details»
Prevention of cardiac, renal and infectious diseases - CorMedix
300 Connell Drive, 4th Floor Suite 4200 Berkeley Heights, NJ 07922 TEL +1 908-517-9500 FAX +1 908-375-8272 DEFENCATH, CORMEDIX, the CORMEDIX logo and CORMEDIX INC ...See details»